Minireview: nucleotide prodrugs

Antiviral Research

Volumn 27, Issue 1-2, 1995, Pages 1-17

  Jones, Robert J ^a   Bischofberger, Norbert ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Enhanced potency; Enhanced selectivity; Increased absorption; Intracellular delivery; Nucleotide prodrug; Reduced toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; IMMUNOMODULATING AGENT; NUCLEOTIDE; PRODRUG; ZIDOVUDINE;

CELL PH; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOXICITY; ENZYME ACTIVITY; HUMAN; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY;

MOLECULAR STRUCTURE; NUCLEOTIDES; PRODRUGS;

EID: 0029015084     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00011-A     Document Type: Review

References (119)

1. 18O] phosphates
2. A simple method for the preparation of the individual diastereoisomers of ribonucleoside 3′5′-cyclic NN-dimethylphosphoramidates
3. The State pronucleotide derivative of ddA: a more potent HIV inhibitor than AZT
4. A highly efficient one-flask method for the preparation of the individual diastereoisomers of ribonucleoside 3′,5′-cyclic N-substituted phosphoramidates via the Appel reaction
5. Synthesis and antitumor and antiviral activities of a series of 1-β-d-ribofuranosyl-5-halocytosine (5-halocytidine) cyclic 3′,5′-monophosphates
6. Synthesis structure and antitumor and antiviral activities of a series of 5-halouridine cyclic 3′5′-monophosphates
7. Studies on fluorinated pyrimidines XVIII
8. Evaluation of nucleotide prodrugs as inhibitors of viral replication
9. 1-[((S)-2-hydroxy-2-oxo-1,4,2,-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo
10. Improved delivery through biological membranes. 1. A redox chemical drug-delivery system and its use for brain-specific delivery of phenylethylamine
11. p)-phosphoramidate, the first representatives of nucleoside cyclic 3′,5′-phosphoramidates derived from ammonia
12. p)-N-methylphosphoramidate
13. Studies of the enzymatic deamination of cytosine arabinoside-I
14. Bis(m-nitrophenyl) and bis(p-nitrophenyl) esters and the phosphorodiamidate of thymidine 5′-phosphate as potential sources of intracellular thymidine 5′-phosphate in mouse cells in culture
15. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine
16. The utilization of nucleotides by animal cells
17. Synthesis and biological evaluation of some phosphate triester derivatives of the anti-cancer drug AraC
18. A phase I/II study of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in advanced HIV infection
19. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vero cells
20. Oral bioavailability of antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys
21. Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: studies on the effect of chain elongation on biological activity
22. Recent advances in the search for selective antiviral agents
23. Therapeutic potential of HPMPC as an antiviral drug
24. Novel phosphate derivatives of zidovudine as anti-HIV compounds
25. Synthesis and reactivity of guanosine 3′,5′-phosphoric acid alkyl esters
26. Synthesis and reactivity of nucleoside cyclophosphate triesters
27. Nucleotide, V: synthese und eigenschaften von uridine-3′,5′-cyclophosphattriestern
28. Synthesis and application of the photolabile guanosine 3′,5′-phosphoric-o-nitrobenzylester
29. Synthesis, structure and reactivity of adenosine cyclic 3′,5′-phosphate benzyl triesters
30. Synthesis and biological evaluation of neutral derivatives of 5-fluoro-2′-deoxyuridine 5′-phosphate
31. A strategy to introduce therapeutic nucleoside 5′-phosphates into cells
32. Synthesis and antitumor evaluation of Bis[(pivaloyloxy)methyl] 2′-deoxy-5-fluorouridine 5′-monophosphate (FdUMP): a strategy to introduce nucleotides into cells
33. Synthesis and biological properties of novel phosphotriesters: a new approach to the introduction of biologically active nucleotides into cells
34. Preparation and behavior of simple quinone methides
35. Selective inhibition of ectromelia virus DNA synthesis in hepatocytes by adenine β-d-arabinofuranoside (ARA-A) and adenine-β-d-arabinofuranosyl-5′-monophosphate (ARA-AMP) conjugated to asialofetuin
36. Hepatocyte targeting of adenine 9-β-d-arabinofuranosyl-5′-monophosphate (ara-AMP) coupled to lactosaminated albumin
37. Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver
38. Drug targeting in antiviral chemotherapy
39. In vitro and in vivo antiviral (RNA) evaluation of orotidine 5′-monophosphate decarboxylase inhibitors and analogues including 6-azauridine-5′-(ethylmethoxyalaninyl)phosphate (a 5′-monophosphate prodrug)
40. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells
41. Antiviral phosphate prodrugs
42. Lipophilic phosphorus prodrugs for the antiviral agent PMEA
43. A pro-drug of zidovudine with enhances efficacy against human immunodeficiency virus
44. Synthesis and properties of some cyclic AMP alkyl phosphotriesters
45. 6- and 1-substituted mannosyl phosphotriesters as lipophilic macrophage-targeted carriers of antiviral nucleosides
46. Potent DNA chain ternimation activity and selective inhibition of human immunodeficiency virus reverse transciptase by 2′,3′-dideoxyuridine-5′-triphosphate
47. Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study, and antiviral activity
48. Novel nucleoside strategies for anti-HIV and anti-HSV therapy
49. Distribution of kinase and deaminase of 1 β-d-arabinofuranosylcytosine in tissues of man and mouse
50. Isopolar phosphorous-modified nucleotide analogues
51. Synthesis and antitumor activity of 1-β-d-arabinofuranosylcytosine conjugates of cortisol and cortisone
52. Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(β-d-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone
53. Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(β-d-arabinofuranosyl)cytosine conjugates of corticosteroids
54. Nucleoside conjugates. 6. synthesis and comparison of antitumor activity of 1-β-d-arabinofuranosylcytosine conjugates of corticosteroids and selected lipophilic alcohols
55. Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides
56. Phosphatidylazidothymidine: mechanism of antiretroviral action in CEM cells
57. Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice
58. Phosphatidylazidothymidine and phosphatidyl-ddC: Assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in rauscher leukemia virus-infected mice
59. Synthesis and biological properties of some cyclic phosphotriesters derived from 2′-deoxy-5-fluorouridine
60. Monophosphoric acid diesters of 7β-hydroxycholesterol and of pyrimidine nucleosides as potential antitumor agents: synthesis and preliminary evaluation of antitumor activity
61. Synthesis properties and biological activity of some nucleoside cyclic phosphoramidates
62. Synthesis of diribonucleoside phospho(P → N)-amino acid derivatives
63. A simple synthesis of adenosine 3′5′-cyclic phosphate alkyl triesters
64. Alkylated cAMP derivatives: selective synthesis and biological activities
65. A convenient synthesis of adenosine 3′,5′-cyclic phosphate (cAMP) benzyl and methyl triesters
66. Comparison of antiviral effects of zidovudine phosphoramidate and phosphorodiamidate derivatives against HIV and ULV in vitro
67. Antitumor activity and pharmacology of 1-β-d-arabinofuranosylcytosine-5′-stearylphosphate: an orally active derivative of 1-β-d-arabinofuranosylcytosine
68. The effects of adenosine- and guanosine 3′,5′-phosphoric acid benzyl esters on guinea-pig ventricular myocardium
69. Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives
70. Synthesis of lipophilic phosphate triester derivatives of 5-fluorouridine and arabinocytidine as anticancer prodrugs
71. The metabolism of exogenously supplied nucleotides by Escherichia coli
72. Synthesis and toxicological properties of three naturally occurring cyanoepithioalkanes
73. Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA
74. Synthesis and evaluation of some novel phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT) as anti-HIV compounds
75. Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT and ddCyd
76. Synthesis of some novel dialkyl phosphate derivative of 3′-modified nucleosides as potential anti-AIDS drugs
77. Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound
78. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT
79. Phosphoramidate derivatives of AZT as inhibitors of HIV: studies on the carboxyl terminus
80. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT
81. Alkyl hydrogen phosphonate derivatives of the anti-HIV agent AZT may be less toxic than the parent nucleoside analogue
82. Synthesis of purine nucleoside 3′5′-cyclic phosphoramidates
83. Studies on neutral esters of cyclic AMP
84. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug
85. Time course of the increase in the myocardial slow inward current after a photochemically generated concentration jump of intracellular cAMP
86. The question of chair-twist equilibria for the phosphate rings of nucleoside cyclic 3′,5′-monophosphates
87. New photoactivatable cyclic nucleotides produce intracellular jumps in cyclic AMP and cyclic GMP concentrations
88. Synthesis and transmembrane transport studies by NMR of a glucosyl phospholipid of thymidine
89. Treatment of myelodysplastic syndromes with orally administered 1-β-d-arabinofuranosylcytosine-5′-stearylphosphate
90. A dihydropyridine carrier system for sustained delivery of 2′,3′-dideoxynucleosides to the brain
91. Activity of BRL47923 and its oral prodrug, SB203657A against a rauscher murine leukemia virus infection in mice
92. Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity
93. Decomposition pathways of the mono- and bis(pivaloyloxymethyl) esters of azidothymidine-5′-monophosphate in cell extract and in tissue culture medium: an application of the ‘on-line ISRP-cleaning’ HPLC technique
94. Cyclic AMP and cyclic GMP
95. Synthesis and antiherpes virus activity of phosphate and phosphonate derivatives of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96. Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process
97. Toxicological assessment and health standard ratings for ethylene sulfide in the industrial atmosphere
98. The potential of nucleotide analogs as inhibitors of retroviruses and tumors
99. 4-acyl and 2,2′-anhydro-3′-0-acyl derivatives as potential prodrugs
100. Increased sensitivity of the walker tumour towards aromatic nitrogen mustards carrying basic side chains following glucose pretreatment
101. Synthesis of some nucleotides derived from 3′-deoxythymidine
102. Phospholipid-nucleoside conjugates 3 Synthesis and preliminary biological evaluation of 1-β-d-arabinofuranosylcytosine 5′-monophosphate-l-12-dipalmitin and selected 1-β-d-arabinofuranosylcytosine 5′-diphosphate-l-12-diacylglycerols
103. The degradation of 5-iododeoxyuridine and 5-bromodeoxyuridine by serum from different sources and its consequences for the use of these compounds for incorporation into DNA
104. Synthetic nucleosides and nucleotides. XVI. Synthesis and biological evaluations of a series of 1-β-d-arabinofuranosylcytosine 5′-alkyl or arylphosphates
105. Membrane-permeable dideoxyuridine 5′-monophosphate analogue inhibits human immunodeficiency virus infection
106. Oral bioavailability of PMEA from PMEA prodrugs in male Sprague-Dawley rats
107. A facile one-step synthesis of 5′-phosphatidylnucleosides by an enzymatic two-phase reaction
108. A facile enzymatic synthesis of 5′-(3-sn-phosphatidyl)nucleosides and their antileukemic activities
109. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice
110. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates
111. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine
112. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA)
113. Synthesis bioactivation and anti-HIV activity of the bis(4-acyloxybenzyl) and mono(4-acyloxybenzyl) esters of the 5′-monophosphate of AZT
114. Adenosine cyclic 3′5′-phosphoramidate and NN-dimethylphosphoramidate synthesis via symmetrical and mixed anhydrides and hydrolysis
115. AIDS dementia: synthesis and properties of a derivative of 3′-azido-3′-deoxythymidine (AZT) that may become ‘locked’ in the central nervous system
116. Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques
117. A phase I/II study of PMEA in HIV infected patients
118. Cellular pharmacology of 2′,3′-didehydro-2′,3′-dideoxy-thymidine (D4T) in human peripheral blood mononuclear cells